Glasdegib is a small molecule inhibitor of the Hedgehog signaling pathway that functions by binding to the smoothened (SMO) receptor. It is clinically indicated for the treatment of newly diagnosed acute… Read more
Glasdegib is a small molecule inhibitor of the Hedgehog signaling pathway that functions by binding to the smoothened (SMO) receptor. It is clinically indicated for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years of age or older, or those with comorbidities that preclude the use of intensive induction chemotherapy. To support the rigorous analytical requirements for this targeted therapy, this category provides comprehensive reference standards for the parent drug, including its critical impurities, degradants, and relevant metabolites. Pharmaceutical laboratories and research facilities rely on these high-purity reference materials, as well as stable isotope labelled compounds, to conduct accurate impurity profiling, method validation, and ongoing quality control throughout drug development and manufacturing. These materials ensure that analytical methods remain robust and compliant with established quality protocols for the assessment of this complex pharmaceutical agent.